Overview

Evaluate the safety, tolerance and efficacy of hydroxychloroquine sulfate tablets the prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy

Eligibility

Inclusion Criteria:

• Patients pathologically diagnosed with non-metastatic head and neck malignant tumors
• Aged 18-80 years
• Eastern Cooperative Oncology Group performance status of ≤2
• Planning to receive definitive RT or postoperative adjuvant RT
• Normal liver, kidney and bone marrow function
• Sign informed consent

Exclusion Criteria:

• Those who are known to be allergic to 4-aminoquinoline compounds or have more serious allergic constitution
• Had a history of head and neck radiotherapy
• Patients with non head and neck parts in the radiotherapy area
• Poor oral hygiene or severe periodontitis
• Suffering from severe kidney disease, severe cardiovascular disease, myasthenia gravis, Parkinson's disease or epilepsy
• Recently taking or taking diuretics or other drugs known to interact with hydroxychloroquine sulfate tablets
• Retinopathy
• Other patients (combined with any serious other diseases) who the investigator believes are not suitable for participation in this study